Authors:
Maha M. AbdelrahmanBeni-Suef University, Beni-Suef, 62514, Egypt

Search for other papers by Maha M. Abdelrahman in
Current site
Google Scholar
PubMed
Close
,
Nada S. AbdelwahabBeni-Suef University, Beni-Suef, 62514, Egypt

Search for other papers by Nada S. Abdelwahab in
Current site
Google Scholar
PubMed
Close
,
Ahmed A. TahaNahda University, Beni-Suef, 62514, Egypt

Search for other papers by Ahmed A. Taha in
Current site
Google Scholar
PubMed
Close
, and
John M. BoshraNahda University, Beni-Suef, 62514, Egypt

Search for other papers by John M. Boshra in
Current site
Google Scholar
PubMed
Close
Restricted access

The presented study was intended to design two validated, simple, and precise chromatographic methods for the determination of chlorzoxazone (CHZ) and diclofenac potassium (DIC) in the presence of chlorzoxazone nephrotoxic degradation product, 2-amino-4-chlorophenol (ACP) which was reported to be its main impurity. Reversed-phase high-performance liquid chromatography (RP-HPLC) was the first method where chromatographic separation was performed on ZORBAX Eclipse Plus C8 column using methanol—water—phosphoric acid (75:25:0.05, by volume) as the mobile phase at a flow rate of 1 mLmin−1. CHZ, DIC, and ACP retention times were found to be 4.26, 7.94, and 3.17, respectively, using photodiode array detector (DAD) at 230 nm. The calibration curves showed good linear relationships in the concentration ranges of 3–45 μg mL−1 for CHZ, 3–40 μg mL−1 for DIC, and 5–45 μg mL−1 for ACP. The second method was thin-layer chromatography (TLC) at which chromatographic separation was carried out on Merck TLC silica gel 60 F254 aluminum plates followed by measurement of separated bands at 230 nm and using chloroform—ethanol—triethylamine (9:1:0.1, by volume) as the developing system. The studied components were successfully separated with significantly different R f values (CHZ, R f = 0.63; DIC, R f = 0.35; ACP, R f = 0.42). Linearity was constructed in the range of 1.2–5 μg band−1 for CHZ, 0.5–4 μg band−1 for DIC, and 0.4–4 μg band−1 for ACP. The developed methods were applied to Declophen plus® capsules, and no interference from excipients was observed. The methods were validated as per the United States Pharmacopeia (USP) guidelines, and they were compared favorably with the reported method.

  • [1]

    The United States Pharmacopeia, 32nd edn., National Formulary 27, United States Pharmacopeial Convention, Rockville, MD, 2009.

  • [2]

    M. M. Ellaithy , N. A. El-Regehy, M. A. El-Ghobashy, Il Farmaco 58 (2003) 337342.

  • [3]

    E. A. Abdelaleem , N. S. Abdelwahab, J. Chromatogr. Sci. 51 (2013) 187191.

  • [4]

    M. A. Badgujar, S. G. Pingale, K. V. Mangaonkar, E-J. Chem. 8 (2011) 12061211.

  • [5]

    R. Panchumarthy , D. R. Garikapati, A. Akaula, S. B. Puttagunta, J. Chem. Pharm. Sci. 6 (2013) 181188.

  • [6]

    J. T. Stewart , Anal. Profiles Drug Subst. Excipients 16 (1987) 119144.

  • [7]

    British Pharmacopoeia, Vol. I, Stationery Office, Medicines and Healthcare Products Regulatory Agency, London, 2003, pp. 605–606.

  • [8]

    R. A. Patel , S. H. Joshi, World J. Pharm. Pharm. 3 (2014) 12791291.

  • [9]

    Sigma-Aldrich Catalogue; www.sigmaaldrich.com; accessed on 16 April, 2016.

  • [10]

    Hazardous Chemicals Fact Sheet, New Jersey Department of Health and Senior Services, Trenton, NJ, 1996.

  • [11]

    F. F. Belal , M. K. Sharaf El-Din, F. A. Aly, M. I. El-Awady, Int. J. Pharma. Sci. Res. 2 (2011).

  • [12]

    S. A. Patel , K. M. Prajapati, Int. J. ChemTech Res. 5 (2013) 20352040.

  • [13]

    K. M. Prajapati , Int. J. Pharmamedix India 1 (2013) 258269.

  • [14]

    S. A. Patel , K. M. Prajapati, Pharmatutor (2013) 19; (http://www. pharmatutor. org/articles/development-and-validation-rp-hplcmethod- for-simultaneous-estimation-of-chlorzoxazone-diclofenac- sodium-in-combination).

    • Search Google Scholar
    • Export Citation
  • [15]

    M. S. Bhatia , S. G. Kaskhedikar, S. C. Chaturvedi, Indian Drugs 34 (1997) 149153.

  • [16]

    S. Ravisankar , M. Vasudevan, M. J. Nanjan, Bijukurian, B. Suresh, Indian Drugs 34 (1997) 663665.

  • [17]

    J. L. Chawla , R. A. Sodhi, R. T. Sane, Indian Drugs 33 (1996) 171178.

  • [18]

    A. Goyal , S. Jain, Acta Pharm. Sci. 49 (2007) 147151.

  • [19]

    M. B. Kulkarni , P. B. Dange, S. G. Walode, J. Pharm. Sin. 3 (2012) 643652.

  • [20]

    S. Pawar , A. Kale, M. Amrutkar, A. Bhosale, Asian J. Res. Chem. 2 (2009) 306308.

  • [21]

    R. Ganesh , U. J. Dhorda, M. Sundaresan, Indian Drugs 38 (2001) 483486.

  • [22]

    J. Patel , P. Patel, Int. J. Pharm. Pharm. Sci. 6 (2014) 632637.

  • [23]

    The United States Pharmacopeia, National Formulary 35, United States Pharmacopeia Convention Inc., 30th edn., Rockville, MD, 2012.

  • [24]

    M. M. Srivastava , High P erformance Thin L ayer Chromatography (HPTLC), Springer, Heidelberg, Dordrecht, London, 2011, p. 3338.

  • [25]

    The United States Pharmacopeia “National Formulary USP”; The Official Compendia of Standards, USP 34-NF 29, Rockville, MD, 2011.

  • Collapse
  • Expand

To see the editorial board, please visit the website of Springer Nature.

Manuscript Submission: HERE

For subscription options, please visit the website of Springer Nature.

Journal of Planar Chromatography - Modern TLC
Language English
Size A4
Year of
Foundation
1988
Volumes
per Year
1
Issues
per Year
6
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Springer Nature Switzerland AG
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0933-4173 (Print)
ISSN 1789-0993 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2022 8 0 0
Jul 2022 14 0 0
Aug 2022 5 0 0
Sep 2022 4 0 0
Oct 2022 3 0 0
Nov 2022 8 0 0
Dec 2022 0 0 0